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Abstract Retroviruses have been etiologically implicated with 
leukemia in humans and animals. Understanding the virus life 
cycle, the proteins and enzymes involved in its replication, is 
essential for developing potent anti-viral drugs. Phosphorylation 
of retroviral proteins may alter their shape in such a way as to 
increase or inhibit their biological activities and thus influence 
the replication and pathogenic potential of the retroviruses. In 
our previous work, we demonstrated that non-cytotoxic doses of 
tyrphostins (protein tyrosine kinase blockers) inhibit moloney 
murine leukemia virus (Mo-MuLV) replication in acutely and 
chronically infected cells. In an attempt o understand their mode 
of action as anti-MoMuLV drugs, we examined the possibility 
that a viral protein is phosphorylated in tyrosine. Indeed, in our 
present work, we show that the p15 matrix protein (MA) of Mo- 
MuLV is a phosphotyrosine protein and is the only viral protein 
which is phosphorylated on tyrosine. Moreover, treatment of 
Mo-MuLV/NIH/3T3 chronically infected cells with tyrphostin 
AG-555 specifically inhibits the synthesis of p15 and other viral 
proteins but does not affect the synthesis of cellular proteins. Our 
results suggest hat tyrosine phosphurylation of p15 MA protein 
may play a pivotal role in Mo-MuLV replication. 
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1. Introduction 
The biological activity of proteins is often, but not always, 
influenced by phosphorylation on serine, threonine or tyrosine 
residue in the protein. Phosphorylation can alter the shape of 
the protein in such a way as to increase or inhibit its biolo- 
gical activity. Since certain retroviruses are the causative 
agents for severe diseases in humans and animals, regulation 
of their protein activity by phosphorylation may influence 
their replication and pathogenic potential. Phosphorylation 
of retrovirus proteins was demonstrated in several studies, 
i.e., in moloney murine leukemia virus proteins such as 
pr65 gag, p12 [1], p30 [2]; in rous sarcoma virus proteins such 
as the integrase [3]; and in human immunodeficiency virus 
proteins such as Nef [4,5], pr55 g~g and p17 [6,7], Vpu [8-10] 
and Rev [11]. The predominant phosphoamino acids in these 
proteins were phosphoserine and/or phosphothreonine. Tyro- 
sine phosphorylation of retroviral protein was recently dem- 
onstrated in HIV matrix protein (MA) [12] and it was shown 
that a direct interaction between tyrosine-phosphorylated MA 
and the central domain of the integrase governed the HIV 
nuclear import [13]. 
We have recently demonstrated that tyrphostin, protein ty- 
rosine kinase blockers, inhibited Mo-MuLV replication in 
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acutely and chronically MoMuLV/NIH/3T3 infected cells 
[14]. We also showed that this compound inhibited the inte- 
gration process of the proviral DNA into the host cell genome 
in acutely infected cells and viral protein synthesis in chroni- 
cally infected cells (manuscript submitted). It was also recently 
demonstrated that certain tyrphostin derivatives inhibited the 
HIV-1 integrase activity in an in vitro assay [15]. Taking all 
these data into account, we suggest hat tyrosine phosphory- 
lation may play a crucial role in retrovirus replication. There- 
fore, we examined the possible xistence of tyrosine phosphor- 
ylation in Mo-MuLV proteins and the effect of tyrphostin on 
this phosphorylation. We found that the Mo-MuLV p15 g~g is 
phosphorylated on tyrosine and treatment of the Mo-MuLV/ 
NIH-3T3 chronically infected cells with non-cytotoxic doses 
of tyrphostins resulted in the inhibition of viral protein syn- 
thesis and notably decreased the level of p15. 
2. Materials and methods 
2.1. Cells 
NIH/3T3-Mo-MuLV chronically infected cells were grown in Dull- 
becco's modified Eagle medium supplemented with 10% fetal calf 
serum, 1% penicillin-streptomycin and1% L-glutamine. 
2.2. Virus preparation 
The culture supernatant of NIH/3T3/Mo-MuLV chronically in- 
fected cells (106/ml) was collected and centrifuged (3000 rpm, 10 
min). The virus was purified twice from the culture medium by pre- 
cipitation using ultracentrifugation (30000 rpm, 3 h, 4°C) through a 
cushion of 5% ficol in TE (10 mM Tris.HC1, pH 8, 1 mM EDTA). To 
remove traces of ficol, the virus pellet was resuspended in TE and 
precipitated by ultracentrifugation, resuspended again in TE and 
stored in aliquots at -700C for further analysis. 
2.3. Antibodies 
Anti-pl5 gag, anti-gp70, anti-total Mo-MuLV proteins antibodies 
were obtained from Donald G. Blair, NCI/ NIH Frederick Cancer 
Research and Development Center, Frederick, MD, USA. Anti-phos- 
photyrosine antibodies were purchased from Transduction Labora- 
tories. Phosphotyrosine, phosphoserine and phosphothreonine w re 
purchase from Sigma. Tyrphostin AG-555 was received from A. Le- 
vitzki and A. Gazit, the Hebrew University, Jerusalem, Israel. Stock 
solutions of the drugs, 10 mM in 100% DMSO were stored at -20°C. 
2.4. Immunoprecipitation andWestern blot analysis 
Viral particles were lysed with 0.3% NP-40 at 37°C for 20 min and 
50 pg of viral proteins was incubated overnight at 4°C with anti-pl5 
antibodies (1: 500 dilution), or anti-total antibodies (1: 500 dilution). 
Protein A-sepharose (0.1 gr/ml) was added for 1 h at 4°C and the 
immunocomplexes were precipitated by centrifugation with microcen- 
trifuge (13 000 rpm, 2 min). The pellet was washed 3 times with RIPA 
buffer (50 mM Tris-HC1, 0.5 M Na2HPO4, 0.5% NP-40, 0.25% so- 
dium deoxycholate, 0.5% SDS). Samples were analyzed on 10% SDS- 
polyacrylamide gel electrophoresis (PAGE) and the proteins were 
transferred to a nitrocellulose membrane as described [16]. The mem- 
brane was reacted with anti-phosphotyrosine a tibodies or after strip- 
ping, it was reprobed with anti-pl 5 antibodies (1:5000 dilution). The 
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blot was developed by the Western blotting detection reagents; en- 
hanced chemiluminescence (ECL) (Amersham). 
2.5. Two-dimensional ge analysis 
The two-dimensional gel analysis (2D-gel) was performed as de- 
scribed by O'Farell [17]. Viral proteins (50 Ixg) were immunoprecipi- 
tated by anti-total antibodies and subjected to 2D-gel analysis. The 
proteins were visualized by silver staining or were transferred to ni- 
trocellulose membrane for Western blot analysis. 
2.6. Metabolic labeling of viral proteins with [32P]orthophosphate 
NIH/3T3/Mo-MuLV chronically infected cells (106 cells/flask) were 
incubated with a medium depleted from phosphate for 24 h followed 
by incubation with fresh medium containing [32P]orthophosphate (2.5 
mCi) for 18 h. The culture medium was collected after 24 h and the 
virus particles were precipitated by ultracentrifugation (30000 rpm, 
3 h, 4°C). The virus particles were suspended in TE (10 mM Tris-HC1 
pH 8, 1 mM EDTA) and lysed by 0.03% NP-40. Viral proteins were 
immunoprecipitated with anti-total antibodies and subjected to SDS- 
PAGE and autoradiography. 
3. Results 
3.1. The Mo-MuLV pl5 gag protein & recognized by 
anti-phosphotyrosine antibodies 
Purified Mo-MuLV particles were lysed and immunopreci- 
pitation with anti-pl5 or anti-Mo-MuLV total proteins or 
anti-phosphotyrosine antibodies was performed. The immu- 
nocomplexes were subjected to Western blot analysis using 
anti-phosphotyrosine a tibodies (Fig. 1, panel A). The same 
nitrocellulose membrane underwent the stripping procedure to 
remove the anti-phosphotyrosine a tibodies and was reprobed 
with anti-pl5 antibodies (Fig. 1, panel B). We found that the 
phosphotyrosine antibodies immunoprecipitated a protein of 
15 kDa (Fig. 1, lane 1A) which was also recognized by anti- 
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Fig. 1. The p15 gag protein from Mo-MuLV is recognize by anti- 
phosphotyrosine antibodies. Purified virus particles were lysed with 
0.03% NP-40 at 37°C for 20 min and 50 ~tg of viral proteins were 
subjected to immunoprecipitation by anti-total Mo-MuLV antibod- 
ies (lanes 1A and 1B), or anti-pl5 antibodies (lanes 2A and 2B), or 
anti-phosphotyrosine a tibodies (lanes 3A and 3B). Western blot 
analysis was performed using anti-phosphotyrosine a tibodies (panel 
A). The nitrocellulose membrane was subjected to stripping proce- 
dure followed by reprobing with anti-pl5 antibodies (panel B). The 
immuno-complexes were detected by ECL-Western blotting detec- 
tion reagents (Amersham). 
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Fig. 2. Phosphotyrosine compete out the binding of anti-phospho- 
tyrosine antibodies to p15 protein. Viral proteins were 
immunoprecipitated with anti-pl5 antibodies and the immunocom- 
plexes were subjected to Western blot analysis using anti-phospho- 
tyrosine antibodies (lane A) and in the presence of 1 mM phospho- 
serine (lane B) or 1 mM phosphothreonine (lane C) or 1 mM 
phosphotyrosine (lane D). 
p15 antibodies (Fig. 1, lane 1B). When the viral proteins were 
immunoprecipitated with anti-pl5 or anti-total antibodies and 
the Western blot was performed with anti-phosphotyrosin 
antibodies, a 15 kDa protein was again recognized by the 
anti-phosphotyrosine antibodies (Fig. 1, lanes 2A and 3A). 
This 15 kDa protein is also recognized by the anti-pl5 anti- 
bodies (Fig. 1, lanes 2B and 3B). The protein bands of 43 kDa 
and 28 kDa observed in Fig. 1A are the heavy and light 
chains of the immunoglobulins that are phosphorylated on 
tyrosine. 
To rule out the possibility that a 15 kDa phosphotyrosin 
protein from a cellular origin is present in the culture medium, 
a mock preparation of virus particles from NIH/3T3 unin- 
fected cells was performed and underwent the same imuno- 
precipitation and Western blot procedures as the virus prep- 
aration. No protein bands were detected in the mock 
preparation from uninfected cells (data not shown). 
To examine the binding specificity of the anti-phosphotyro- 
sine antibodies to the p15, we performed competition experi- 
ments using phosphotyrosine, phosphothreonine and phos- 
phoserine. The anti-phosphotyrosine antibodies were 
incubated with 1 mM of each of the phosphoamino acids 
followed by Western blot assay. The results depicted in Fig. 
2 demonstrated that only phosphotyrosine can compete out 
the binding of the anti-phosphotyrosine a tibodies to the p15 
protein (compare Fig. 2, lanes D to A, B, and C) indicating 
that this protein is phosphorylated on tyrosine. 
3.2. Separation between the p15 proteins by two-dimensional 
gel electrophoresis 
The 15 kDa protein band that was recognized by the anti- 
p15 and anti-phosphotyrosine antibodies could have more 
than one polypeptide protein in this size. To examine this 
possibility, immunoprecipitation of viral proteins with anti- 
total antibodies was performed and the immunocomplexes 
were subjected to 2D-gel electrophoresis. The protein bands 
were visualized by silver staining (Fig. 3A) or transfered to 
nitrocellulose membrane for further analysis. The membrane 
was first reacted with anti-phosphotyrosine a tibodies (Fig. 
3B) and after stripping procedure the membrane was reprobed 
with anti-pl5 antibodies (Fig. 3C). Two basic proteins in the 
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Fig. 3. Two forms of tyrosine phosphorylated p15 were observed by 
two-dimensional gel analysis. Viral proteins were immunoprecipi- 
tated with anti-total Mo-MuLV protein antibodies and subjected to 
2D-gel analysis. Panel A demonstrates the viral proteins visualized 
by silver staining. Western blot analysis was performed using anti- 
phosphotyrosine antibodies (panel B). The nitrocellulose membrane 
was subjected to a stripping procedure and reprobed with anti-pl5 
antibodies (panel C). 
size of 15 kDa and 15.5 kDa were recognized by the anti- 
phosphotyrosine (Fig. 3A) and anti-pl5 antibodies (Fig. 3B). 
In most mammalian retroviruses the MA domain of the Gag 
precursor is cotranslationally modified at the N-terminus by 
attachment of myristic acid [18]. Therefore, it is possible that 
the two basic proteins are two forms of the Mo-MuLV MA 
(p15) protein in which one is modified by myristic acid and 
both forms are probably phosphorylated on tyrosine. 
3.3. Metabolic labeling of the p15 protein 
Metabolic labeling by 32p of Mo-MuLV proteins was per- 
formed previously [1,2]. It was shown that the phosphoryla- 
tion event of viral proteins, except the p12, was difficult to 
detect because p12 the major virion phosphoprotein i corpo- 
rated almost all the 32p label added to infected cells [1]. It was 
calculated that the degree of phosphorylation at the p30 do- 
main of the pr65 gag was only 0.22-0.54%, relative to phos- 
phorylation at the p12 domain [2]. Indeed we found that the 
major phosphoprotein is the viral p12, but in addition a faint 
radioactive band of 15 kDa protein was observed (Fig. 4, lane 
A). The identification of this radioactive band as p15 was 
carried out by immunoblotting with anti-pl5 and anti-total 
antibodies (Fig. 4, lanes C and D, respectively) and we also 
proved that it is the only protein band recognized by the anti- 
phosphotyrosine antibodies (Fig. 4, lane B). 
3.4. Effect of tyrphost& treatment on p15 synthes& and 
phosphorylation 
We previously demonstrated that tyrphostins, protein tyro- 
sine kinases blockers, inhibited Mo-MuLV replication [14]. 
We examined the effect of these compounds on the synthesis 
and phosphorylation of the viral p15. NIH/3T3/Mo-MuLV 
chronically infected cells were treated with non cytotoxic 
doses of tyrphostin AG-555 [14] for 20 h. The viral particles 
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were precipitated from the culture media and Western blot 
analysis using anti-phosphotyrosine antibodies or anti-pl5 
antibodies was performed. The results depicted in Fig. 5 de- 
monstrate that tyrphostin treatment inhibited the synthesis of 
the p15 viral protein (Fig. 5B, compare lanes 3 and 4 to lanes 
1 and 2) and significantly inhibited the tyrosine phosphoryla- 
tion of this protein (Fig. 5A, compare lanes 3 and 4 to lanes 1 
and 2). The inhibitory effect of tyrphostin treatment is not 
unique to the viral p15 since we could observe this inhibitory 
effect on other viral proteins uch as gp70 (Fig. 5C, compare 
lanes 2 and 3 to lane 1). This inhibitory effect of tyrphostin 
treatment appears to be specific to viral proteins since no 
effect on cellular protein such as I]-actin was observed (Fig. 
5D). 
4. Discussion 
Matrix protein of retroviruses carries two motifs, a myris- 
toylation signal and a nuclear localization signal. These two 
signals exert conflicting influences on the subcellular localiza- 
tion of MA. It was shown by Gallay et al. [13] that phosphor- 
ylation of MA protein of HIV-1 on the C-terminal tyrosine 
enable the transportation f this protein to the nucleus. In our 
present work, we showed that the p15 gag, which is the Mo- 
MuLV MA protein, is a phosphotyrosine protein. We also 
demonstrated that the MA protein is the only viral protein 
which is phosphorylated on tyrosine since: (1) Immunoprecip- 
itation of Mo-MuLV proteins by anti-total Mo-MuLV anti- 
bodies and Western blot analysis using anti-phosphotyrosine 
antibodies or anti-pl5 antibodies revealed that the p15 g~g pro- 
tein was the only protein recognized by the anti-phosphotyr- 
osine antibodies. (2) Metabolic labeling of the viral proteins 
by 32p in combination with Western blot analysis using anti- 
phosphotyrosine antibodies howed that among the phos- 
phorylated viral proteins, only the p15 g~g protein was both 
phosphorylated with 32p and recognized by the anti-phospho- 
tyrosine antibodies. Our data are compatible with other stud- 
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Fig. 4. Metabolic labeling of viral proteins with 
[32P]orthophosphate. Viral proteins were labeled with 32p as de- 
scribed in Section 2. Viral lysates were performed and the proteins 
were immunoprecipitated with anti-total Mo-MuLV proteins anti- 
bodies and the immunocomplexes were separated on 15% SDS-poly- 
acrylamide gel followed by transfer to nitrocellulose membrane and 
autoradiography (A) or probed with anti-phosphotyrosine a tibod- 
ies (B) or with anti-pl5 antibodies (c), or with anti-total Mo-MuLV 
antibodies (D). 
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Fig. 5. Treatment of Mo-MuLV/NIH/3T3 chronically infected cells 
with tyrphostin AG-555 inhibit viral protein synthesis. The chroni- 
cally infected cells were treated with 100 ~tM (lanes 3A, 3B and 2C) 
or with 50 ~tM (lanes 4A, 4B and 3C) of tyrphostin AG-555 or 
with 4% DMSO (lanes 2A and 2B) for 20 h. Lanes 1A,1B: un- 
treated ceils. Protein extract from the cells was prepared and 50 Ixg 
of proteins were subjected to 15% SDS-PAGE and Western blot 
analysis was performed using anti-phosphotyrosine antibodies (panel 
A) or anti-pl5 antibodies (panel B) or anti-gp 70 antibodies (panel 
C) or anti-~-actin antibodies (panel D). 
ies that demonstrated that the predominant phosphoamino 
acid in viral phosphoproteins is serine and/or threonine but 
not tyrosine [1-11] and tyrosine phosphorylation was shown 
only on the HIV-1 MA protein [12,13]. The role of the p15 
MA protein in Mo-MuLV life cycle is not clear but studies 
performed with other retroviruses suggest hat it has an im- 
portant role in virus replication and infectivity. For instance, 
it was shown that the MA protein from HIV is involved in the 
virus nuclear import in nondividing cells [13], and in RSV it is 
involved in membrane binding during particle assembly and 
has yet undefined function required for viral infectivity [19]. In 
addition, it was demonstrated that the phosphorylation of 
tyrosine on the C-terminal residue of HIV MA protein en- 
hanced the incorporation of MA into the virus core and is 
required for its association with the uncoated viral nucleopro- 
tein complex [13]. Therefore, inhibition of the tyrosine phos- 
phorylation of MA protein may affect virus replication in the 
infected cells. Indeed, we found that tyrphostin derivatives, 
which are protein tyrosine kinase blockers, inhibited Mo- 
MuLV replication in chronically infected Mo-MuLV/NIH 
3T3 cells. Moreover, we showed that tyrphostin AG-555 spe- 
cifically inhibited the synthesis of viral proteins including the 
p15 MA protein. A similar phenomenon was also demon- 
strated by other investigators who showed that certain tyr- 
phostin derivatives specifically reduced the level of 
pp60F527 protein (encoded by the c-src/F527 gene) but did 
not affect the synthesis of other proteins [20]. Since treatment 
of Mo-MuLV/NIH 3T3 chronically infected cells with tyr- 
phostin AG-555 did not affect viral RNA synthesis (Priel et 
al., manuscript submitted), we may presume that a specific 
protein tyrosine kinase and/or the tyrosine phosphorylation 
of MA protein are involved in viral protein synthesis. How- 
ever, it is also possible that certain cellular phosphotyrosine 
proteins are involved in the virus replication and inhibition of 
their tyrosine phosphorylation by tyrphostins may influence 
virus replication. 
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